High-grade B-cell Lymphoma
📧 Sign up to get email alerts when something new happens for High-grade B-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating mosunetuzumab in combination with chemotherapy for untreated C-MYC rearrangement-positive high-grade B…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma [Phase 2]
Phase 2 clinical trial evaluating the combination of epcoritamab, rituximab, gemcitabine, and oxaliplatin (R-GemOx) as salvage therapy befor…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma [Phase 1]
A Phase 1 clinical trial is evaluating a triple-drug regimen consisting of mosunetuzumab, polatuzumab vedotin, and lenalidomide for relapsed…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma [Phase 1]
Phase 1 clinical trial evaluating mosunetuzumab consolidation after autologous stem cell transplantation in relapsed/refractory aggressive B…
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Lymphoma [Phase 1]
This ClinicalTrials.gov update describes an ongoing Phase 1 study of 19(T2)28z1xx TRAC-CAR T cells in patients with B-cell lymphomas, includ…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas [Phase 2, Phase 3]
A Phase 2/Phase 3 trial is evaluating adding venetoclax to standard chemotherapy for high-grade B-cell lymphomas, including diffuse large B-…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma [Phase 1, Phase 2]
Genmab-sponsored first-in-human trial in relapsed/refractory B-cell lymphomas spans Phase 1/2 and is currently active/not recruiting.
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL) [Phase 1, Phase 2]
Clinical trial update announcing a Phase 1/2 study of epcoritamab in Japanese patients with relapsed or refractory B-cell non-Hodgkin lympho…
-
CLINICAL_TRIALS research · 2026-04-07Clinical Trial Update: Study of CAR-T Therapy in Older Patients
A clinical trial update describing a CAR-T therapy study enrolling older adults with B-cell lymphomas and multiple myeloma, currently recrui…
-
CLINICAL_TRIALS research · 2026-04-03Clinical Trial Update: CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies [Phase 1]
A Phase 1 study of CLIC-2201 for relapsed/refractory B-cell malignancies is currently recruiting. The conditions covered include various B-c…
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma [Phase 2]
Phase 2 trial evaluating first-line Tafasitamab, Polatuzumab Vedotin, and Glofitamab for diffuse large B-cell lymphoma and high-grade B-cell…
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19) [Phase 2, Phase 3]
Clinical trial update for NexCAR19 (Talikabtagene autoleucel), a CAR-T therapy studied in relapsed/refractory B-cell malignancies; the Phase…
-
CLINICAL_TRIALS research · 2026-03-18Clinical Trial Update: A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma [Phase 1]
AstraZeneca reports a Phase 1 clinical trial of AZD0486 in B-cell non-Hodgkin lymphomas, including diffuse large B-cell lymphoma, high-grade…
-
CLINICAL_TRIALS research · 2026-03-16Clinical Trial Update: CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma [Phase 1]
A Phase 1 clinical trial evaluating CD79b-19 CAR T cells for relapsed or refractory non-Hodgkin lymphoma, including several subtypes, is cur…
-
CLINICAL_TRIALS research · 2026-03-16Clinical Trial Update: Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients [Phase 1, Phase 2]
This clinical trial update describes a Phase 1/2 study of TC011 for relapsed/refractory large B-cell non-Hodgkin lymphoma, assessing safety …
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T [Phase 2]
Phase 2 clinical trial evaluating Odronextamab for relapsed or refractory large B-cell lymphomas before CAR-T therapy; the study is currentl…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: Neurocognitive Assessment in Adults Undergoing CD19 Targeted CAR-T Cell Therapy
This clinical trial update describes neurocognitive assessment in adults undergoing CD19-targeted CAR-T cell therapy for certain B-cell lymp…
-
CLINICAL_TRIALS research · 2026-03-10Clinical Trial Update: Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma [Phase 1, Phase 2]
Acalabrutinib is being studied as maintenance therapy in a Phase 1/2 trial for large B-cell lymphomas, including diffuse large B-cell lympho…
-
CLINICAL_TRIALS research · 2026-03-03Clinical Trial Update: Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma [Phase 1, Phase 2]
This document outlines an ongoing Phase 1/2 dose-escalation and dose-expansion trial of MDX2003 in multiple lymphoma types, including Walden…
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies [Phase 1]
Poseida Therapeutics is conducting a Phase 1 trial of P-CD19CD20-ALLO1, an allogeneic CAR-T cell therapy, for several B-cell malignancies an…
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma [Phase 1]
Phase 1 trial evaluating CC-99282 in combination with Rituximab given early after CAR T therapy in patients with relapsed or refractory B-ce…
-
CLINICAL_TRIALS research · 2026-01-29Clinical Trial Update: Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy [Phase 2]
A Phase 2 trial is evaluating whether vaccination with Prevnar 13 before and after CAR-T therapy can enhance cellular and humoral immunity i…
-
CLINICAL_TRIALS research · 2025-12-29Clinical Trial Update: Exploring the Clinical Impact of MYC Aberrations and Their Relationship With Microenvironment in Diffuse Large B Cell Lymphoma and High-Grade B Cell Lymphoma
A recruiting clinical trial investigating how MYC aberrations and the tumor microenvironment affect diffuse large B-cell lymphoma and high-g…
-
CLINICAL_TRIALS research · 2025-12-22Clinical Trial Update: A Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies [Phase 1]
This clinical trial update describes a Phase 1 study of GF-CART01, a CD20/CD19 CAR T cell therapy, evaluating safety and early activity in a…
-
CLINICAL_TRIALS research · 2025-12-18Clinical Trial Update: A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma [Phase 2]
Phase 2 clinical trial evaluating circulating tumor DNA (ctDNA) testing in people with diffuse large B-cell lymphoma and related high-grade …